|Bid||30.19 x 900|
|Ask||39.00 x 900|
|Day's Range||33.52 - 35.00|
|52 Week Range||24.45 - 41.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.27|
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
According to the GuruFocus All-in-One Screener, the following stocks with market caps over $5 billion look cheap since they are trading with low price-sales ratios. Olin Corp. (OLN) is trading around $30.27 with a price-sales ratio of 0.8, a price-earnings ratio of 8.2 and a forward price-earnings ratio of 11.6. The company has a market cap of $5.06 billion and the stock price has risen at an annualized rate of 5% over the last 10 years.
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EnLink ...
Alnylam Pharmaceuticals’ (ALNY) interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
Medicines Co. (MDCO) delivered earnings and revenue surprises of 1.56% and -78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Parsippany, New Jersey-based company said it had a loss of 74 cents per share. Losses, adjusted for one-time gains and costs, were 63 cents per share. The results beat Wall Street expectations. The ...
Medicines Co. (MDCO) reported second-quarter financial results early Wednesday, including a smaller-than-expected profit loss and a revenue miss. Medicines Co. had $162.5 million in cash and cash equivalents as of June 30, compared with $515.4 million at the end of last year.
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Medicines Company (NASDAQ: MDCO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 8:30 AM Eastern Time. ...
Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Drugs - Generic stocks: The Medicines Co. (NASDAQ: MDCO), Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and SCYNEXIS Inc. (NASDAQ: SCYX).
The Medicines Company will host a conference call and audio webcast on Wednesday, August 1, 2018, at 8:30 a.m. EDT to discuss its second-quarter 2018 financial results and operational developments.
Sarissa Capital Management chief investment officer Alex Denner believes President Donald Trump’s criticism of Pfizer is having an impact on how other companies set their prices. “By putting pressure on one particular company, I think all the companies are saying: We don’t want to be Pfizer,” Denner said at the Delivering Alpha Conference. Trump bashed Pfizer and other drugmakers for raising the price of 104 different drugs, arguing that such companies “should be ashamed” for the hikes.
Given their dependence on the success or failure of their drug candidates, biotechnology stocks are generally high-risk propositions. Over the past couple of decades our most profitable sector has been biotech stocks. Of course, the key to almost any stock move is news.
The Delivering Alpha 2018 conference took place Wednesday in New York, and this year’s event included a number of Wall Street heavy-hitters. Benzinga Pro reported live from Delivering Alpha all day long, ...